[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


2. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuele MJ, Jenkins K, Glatstein E, Evans SM: Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res; 2004 Jul 15;10(14):4630-8
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.
  • PURPOSE: Response to photodynamic therapy depends on adequate tumor oxygenation as well as sufficient accumulation of photosensitizer in the tumor.
  • In separate tumor nodules from 10 patients, Photofrin uptake was measured by fluorescence after tissue solubilization.
  • An association between tumor size and hypoxia was not evident because some tumor nodules as small as approximately 2 mm in diameter were severely hypoxic.
  • Three patients with severely hypoxic tumor nodules exhibited moderate levels of Photofrin uptake of 3.9 +/- 0.4 to 3.9 +/- 0.5 ng/mg (mean +/- SE).
  • The four patients with tumors of physiological oxygenation did not consistently exhibit high tumor concentrations of Photofrin: mean +/- SE drug uptake among these patients ranged from 0.6 +/- 0.8 to 5.8 +/- 0.5 ng/mg.
  • These data emphasize the need for reconsideration of the generally accepted paradigm of small tumor size, good oxygenation, and good drug delivery because this may vary on an individual tumor basis.
  • [MeSH-major] Dihematoporphyrin Ether / pharmacokinetics. Etanidazole / analogs & derivatives. Gastrointestinal Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Appendiceal Neoplasms / metabolism. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Benzimidazoles / chemistry. Binding, Competitive / drug effects. Carbocyanines / chemistry. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / therapy. Humans. Hydrocarbons, Fluorinated / chemistry. Hydrocarbons, Fluorinated / metabolism. In Vitro Techniques. Intestine, Small / metabolism. Intestine, Small / pathology. Male. Microscopy, Fluorescence. Oxygen / pharmacology. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15269134.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA75285; United States / NCI NIH HHS / CA / CA85831; United States / NCI NIH HHS / CA / CA87971; United States / NCRR NIH HHS / RR / M01-RR0040
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Benzimidazoles; 0 / Carbocyanines; 0 / Hydrocarbons, Fluorinated; 0 / cyanine dye 3; 23491-52-3 / HOE 33342; 30DKA3Q1HL / Etanidazole; 97067-70-4 / Dihematoporphyrin Ether; S88TT14065 / Oxygen
  •  go-up   go-down


3. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM: Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res; 2006 Sep 15;12(18):5464-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
  • PURPOSE: A phase II trial of Photofrin-mediated i.p. photodynamic therapy shown in a previous report limited efficacy and significant acute, but not chronic, toxicity.
  • A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues.
  • Photofrin uptake was measured by spectroflurometric analysis of drug extracted from tumor and normal tissues removed at surgery.
  • Differences in drug uptake among these tissues were statistically considered using mixed-effects models.
  • In normal tissues, drug uptake significantly (P<0.0001) differed as a function of seven different tissue types.
  • In the toxicity-limiting tissue of intestine, the model-based mean (SE) Photofrin level was 2.70 ng/mg (0.32 ng/mg) and 3.42 ng/mg (0.24 ng/mg) in full-thickness large and small intestine, respectively.
  • In tumors, drug uptake significantly (P=0.0015) differed as a function of patient cohort: model-based mean Photofrin level was 3.32 to 5.31 ng/mg among patients with ovarian, gastric, or small bowel cancer; 2.09 to 2.45 ng/mg among patients with sarcoma and appendiceal or colon cancer; and 0.93 ng/mg in patients with pseudomyxoma.
  • Ovarian, gastric, and small bowel cancers showed significantly higher Photofrin uptake than full-thickness large and/or small intestine.
  • However, the ratio of mean drug level in tumor versus intestine was modest (<or=2.31).
  • CONCLUSIONS: Some selectivity is found in Photofrin uptake between tumor and normal tissues of the peritoneal cavity, but absolute differences in drug uptake relative to toxicity-limiting normal tissues (intestine) are small.
  • This narrow differential in drug selectivity likely contributes to a narrow window in therapeutic application, which has been previously reported.
  • [MeSH-minor] Biopsy. Cohort Studies. Female. Gastrointestinal Neoplasms / drug therapy. Humans. Injections, Intraperitoneal. Models, Biological. Organ Specificity. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-87971; United States / NCI NIH HHS / CA / R01 CA-85831
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol; 2008 May;87(4):410-3
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation.
  • Isolated primary granulocytic sarcoma is a rare disease that presents as an extramedullary tumor of myeloid lineage cells.
  • Herein, we report the case of a 33-year-old woman with a primary isolated granulocytic sarcoma which originated in the small intestine.
  • After she recovered from surgery, she received intensive chemotherapy equivalent to that for AML, followed by allogeneic bone marrow transplantation from an HLA-matched, unrelated donor.
  • This case illustrates the effectiveness of our therapeutic strategy for isolated granulocytic sarcoma, not only with surgical resection of the tumor and intensive chemotherapy equivalent to that for AML, but also with allogeneic bone marrow transplantation, performed while no sign of AML is observed.
  • [MeSH-major] Bone Marrow Transplantation. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Grdina DJ, Murley JS, Kataoka Y, Baker KL, Kunnavakkam R, Coleman MC, Spitz DR: Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):886-96
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.
  • PURPOSE: To determine whether amifostine can induce elevated manganese superoxide dismutase (SOD2) in murine tissues and a transplantable SA-NH tumor, resulting in a delayed tumor cell radioprotective effect.
  • At selected time intervals after the last injection, the heart, liver, lung, pancreas, small intestine, spleen, and SA-NH tumor were removed and analyzed for SOD2, catalase, and glutathione peroxidase (GPx) enzymatic activity.
  • RESULTS: SOD2 activity was significantly elevated in selected tissues and a tumor 24 h after amifostine treatment.
  • If limited to normal tissues, this delayed radioprotective effect offers an additional potential for overall radiation protection.
  • However, amifostine-induced elevation of SOD2 activity in tumors could have an unanticipated deleterious effect on tumor responses to fractionated radiation therapy, given that the radioprotector is administered daily just before each 2-Gy fractionated dose.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] Hum Gene Ther. 2008 Aug;19(8):820-6 [18699723.001]
  • [Cites] Drug Metabol Drug Interact. 2000;16(4):237-79 [11201306.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 15;30(12):1426-39 [11390188.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):135-41 [11774255.001]
  • [Cites] Radiat Res. 2002 Jul;158(1):101-9 [12071809.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2362-78 [12640121.001]
  • [Cites] Radiat Res. 2003 Nov;160(5):568-78 [14565825.001]
  • [Cites] Biochem Biophys Res Commun. 1976 Aug 23;71(4):952-8 [971321.001]
  • [Cites] Br J Radiol. 1978 Apr;51(604):291-301 [647186.001]
  • [Cites] Methods Enzymol. 1984;105:121-6 [6727660.001]
  • [Cites] Clin Exp Metastasis. 1985 Oct-Dec;3(4):281-94 [4075613.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3641-7 [2837320.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] Nucleic Acids Res. 1992 Aug 11;20(15):3821-30 [1508666.001]
  • [Cites] Drug Metab Dispos. 1994 Nov-Dec;22(6):895-902 [7895607.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 1):L588-602 [7491977.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2113-7 [9395210.001]
  • [Cites] Free Radic Biol Med. 1998 Mar 1;24(4):586-93 [9559871.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 7):34-6 [10348258.001]
  • [Cites] DNA Cell Biol. 1999 Sep;18(9):709-22 [10492402.001]
  • [Cites] Radiat Res. 2004 Nov;162(5):536-46 [15624308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):784-91 [16198504.001]
  • [Cites] Free Radic Biol Med. 2006 Mar 15;40(6):1004-16 [16540396.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):465-74 [17388698.001]
  • [Cites] In Vivo. 2007 Mar-Apr;21(2):141-6 [17436562.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):111-8 [17289291.001]
  • [Cites] Oncologist. 2007 Jun;12(6):738-47 [17602063.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4084-9 [17827457.001]
  • [Cites] Gene Ther. 2008 Mar;15(5):347-56 [18097469.001]
  • [Cites] Radiat Res. 2008 May;169(5):495-505 [18439041.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):113-8 [11054513.001]
  • (PMID = 19215822.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099005-04; United States / NCI NIH HHS / CA / P30 CA086862-069012; United States / NCI NIH HHS / CA / P30 CA086862; United States / NCI NIH HHS / CA / R01 CA099005; United States / NCI NIH HHS / CA / P01 CA086862; United States / NCI NIH HHS / CA / R01 CA99005; United States / NCI NIH HHS / CA / CA086862-069012; United States / NCI NIH HHS / CA / CA099005-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mercaptoethylamines; 0 / Radiation-Protective Agents; 31098-42-7 / WR 1065; EC 1.11.1.6 / Catalase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; M487QF2F4V / Amifostine
  • [Other-IDs] NLM/ NIHMS96732; NLM/ PMC2668222
  •  go-up   go-down


6. Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N, Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res; 2003 Nov;27(11):1063-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature.
  • The possibility of an association between the development of granulocytic sarcoma of the small intestine (GSSI) and the M4Eo subtype of AML was suggested in nine previous case reports.
  • Here we report an aleukaemic case of GSSI with inv(16) and its molecular equivalent, the CBFbeta/MYH11 fusion gene, detected by reverse transcriptase-polymerase chain reaction (RT-PCR), that after treatment with conventional AML chemotherapy followed by autologous bone marrow transplantation, achieved complete haematological and molecular remission on bone marrow examination.
  • After chemotherapy, a thickened ileum wall positive for CBFbeta/MYH11 on tumour mass samples was still observed on computed tomography (CT) studies, raising the question of residual GS representing a reservoir of malignant cells.
  • This case demonstrates the critical need of multidisciplinary diagnosis and follow-up of this entity combining immunopathologic, cytogenetic and molecular studies, reinforcing the potentiality of risk-adapted therapy strategies, as it is increasingly claimed for patients with overt AML.
  • [MeSH-major] Intestinal Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Sarcoma, Myeloid / genetics
  • [MeSH-minor] Adult. Humans. Ileum / radiography. Leukemia / complications. Male. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859999.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 24
  •  go-up   go-down


7. Mensah-Osman EJ, Thomas DG, Tabb MM, Larios JM, Hughes DP, Giordano TJ, Lizyness ML, Rae JM, Blumberg B, Hollenberg PF, Baker LH: Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer; 2007 Mar 1;109(5):957-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.
  • The study investigated the hypothesis that the resistance of osteosarcoma to chemotherapy may be related to the expression of a pregnane xenobiotic receptor (PXR) variant protein and its role as the major inducer of P450 3A4 in these tumors.
  • Real-time PCR and CYP3A catalytic activity using 7-benzyl-trifluoromethyl coumarin (BFC) as the probe substrate were used to measure the induction of P450 3A4 or MDR1. siRNA transfections were performed for PXR and cytotoxicity determined by a colorimetric based assay or Annexin v-Fitc staining.
  • RESULTS: Differences were observed in the molecular size of the PXR protein expressed in sarcoma cell lines when compared with the wildtype PXR expressed in normal liver, kidney, or small intestine.
  • A polyclonal PXR antibody raised against the N-terminus of the wildtype PXR did not detect PXR expressed in these sarcoma cell lines.
  • CONCLUSION: The results suggest that PXR plays a critical role in the regulation of P450 3A4 expression in osteosarcoma and that its expression and activation in these tumors may influence the effect of chemotherapeutic agents on the induction of target genes implicated in drug resistance.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827852110 for PMID:17279585 [PharmGKB] .
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1980 Jul;28(7):700-3 [6156203.001]
  • [Cites] Drug Metab Dispos. 2004 Jan;32(1):149-54 [14709632.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jul;294(1):387-95 [10871337.001]
  • [Cites] Nature. 2000 Jul 27;406(6794):435-9 [10935643.001]
  • [Cites] Drug Metab Rev. 2000 Aug-Nov;32(3-4):339-61 [11139133.001]
  • [Cites] Biochem J. 2000 Apr 15;347(Pt 2):321-37 [10749660.001]
  • [Cites] Nat Med. 2001 May;7(5):584-90 [11329060.001]
  • [Cites] Drug Metab Dispos. 2001 Nov;29(11):1454-9 [11602521.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):895-902 [11843823.001]
  • [Cites] Mol Pharmacol. 2002 Sep;62(3):439-45 [12181418.001]
  • [Cites] J Pathol. 2003 Feb;199(2):251-8 [12533839.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):745-52 [12538830.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1619(3):243-53 [12573484.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17277-83 [12611900.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4446-54 [12970323.001]
  • [Cites] Oncologist. 2003;8(5):411-24 [14530494.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):43919-27 [12920130.001]
  • [Cites] Drug Metab Dispos. 2004 Sep;32(9):993-1000 [15319341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2470-5 [14983033.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2047-53 [15026342.001]
  • [Cites] J Pharm Sci. 2004 Aug;93(8):2142-57 [15236461.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):353-66 [3973646.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1208-16 [2504890.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):815-20 [7828131.001]
  • [Cites] Nat Med. 1995 Mar;1(3):267-71 [7585045.001]
  • [Cites] Anal Biochem. 1997 May 15;248(1):188-90 [9177742.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8 [9272126.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):572-9 [9344324.001]
  • [Cites] Drug Metab Dispos. 1997 Dec;25(12):1359-69 [9394025.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3195-205 [9784494.001]
  • [Cites] Steroids. 1999 May;64(5):310-9 [10406480.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 5;260(2):377-81 [10403778.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2103-7 [10473093.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):177-86 [15630458.001]
  • [Cites] Essays Biochem. 2004;40:27-39 [15242337.001]
  • [ErratumIn] Cancer. 2013 Mar 1;119(5):1115
  • (PMID = 17279585.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092739-01A1; United States / NCI NIH HHS / CA / R21 CA092739; United States / NCI NIH HHS / CA / R21 CA092739-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Steroid; 0 / pregnane X receptor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; VJT6J7R4TR / Rifampin
  • [Other-IDs] NLM/ NIHMS301306; NLM/ PMC3125968
  •  go-up   go-down


8. Rénard C, Girard S, Pracros JP, Dijoud F, André JM, Mialou V, Bertrand Y: [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases]. Arch Pediatr; 2010 Feb;17(2):149-53
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases].
  • Granulocytic sarcoma (GS) is a rare extramedullary tumor frequently associated with acute myeloblastic leukemia (AML).
  • We report 3 cases of pediatric granulocytic sarcomas with various locations: skin, orbit, and bowel.
  • In all 3 cases, the diagnosis was delayed or initially missed.
  • GS is treated with chemotherapy, like AML.
  • [MeSH-major] Facial Neoplasms / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Bone Marrow / pathology. Bone Marrow Transplantation. Child, Preschool. Combined Modality Therapy. Diagnostic Errors. Female. Follow-Up Studies. Humans. Infant. Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / drug therapy. Leukemia, Biphenotypic, Acute / pathology. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19945260.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Beyrouti ML, Abid M, Beyrouti R, Ben Amar M, Gargouri F, Frikha F, Affes N, Boujelbene S, Ghorbel A: [Sarcomas of the small intestine]. Presse Med; 2005 Mar 12;34(5):385-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcomas of the small intestine].
  • Sarcomas of the small intestine are rare, clearly differentiated, malignant, mesenchymatous tumours that can be of smooth muscle, Schwann cell or fibroblastic origin.
  • From a clinical point of view, the pain and abdominal mass are the 2 types of symptoms that frequently reveal the disease.
  • In rare cases, sarcomas of the small intestine are manifested by an acute complication.
  • No imaging method can clearly confirm the diagnosis.
  • Before immunohistochemistry, differential diagnosis was made on undifferentiated mesenchymatous "stromal" tumours, which are also rare.
  • The benefits provided by chemotherapy and radiotherapy are limited because of the low mitotic activity of the tumour cells and its weak vascularisation.
  • Long-term survival is limited by poor prognosis criteria: high grade malignancy, size greater than 5 cm, tumour extension, perforation of the tumour, quality of surgical resection and histological type.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859576.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 46
  •  go-up   go-down


10. Lee SY, Park SJ, Kim YH, Lee JH: Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel. Int J Clin Oncol; 2008 Oct;13(5):467-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel.
  • Granulocytic sarcoma (GS) is defined as a localized tumor mass composed of myeloid blasts and/or immature myeloid cells in an extramedullary site.
  • In rare cases, it occurs as a "preleukemic" condition and may precede the onset of AML, which occurs within several months if the patient is not treated with AML-type systemic chemotherapy.
  • Recently, we discovered one case of nonleukemic GS in the small intestine incidentally when intussusception was suspected.
  • The patient visited the emergency department, in October 2006, with symptoms of small-bowel obstruction.
  • Intussusception due to a small-intestinal mass was suspected after evaluation, and small-intestine segmental resection was performed.
  • The patient received three cycles of chemotherapy, applied as for AML (cytosine arabinoside and anthracycline), and is currently, as of October 29, 2007, showing no other marked indisposition; he has been disease-free for 12 months.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small. Intussusception / diagnosis. Sarcoma, Myeloid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1570-4 [17090205.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):912-7 [2423654.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • (PMID = 18946761.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Svrcek M, Tiret E, Bennis M, Guyot P, Fléjou JF: KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. Dis Colon Rectum; 2009 Jan;52(1):154-8
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case.
  • Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), has been identified in all four forms of Kaposi's sarcoma (classic, endemic, HIV-associated and iatrogenic).
  • We report the rare case of an intestinal (small intestine and rectosigmoid) Kaposi's sarcoma in a 62-year-old HIV-negative man with ulcerative colitis.
  • This patient was receiving immunosuppressive therapy with steroids and azathioprine.
  • To date, the causative role of KSHV/HHV8 in the pathophysiology of Kaposi's sarcoma associated with ulcerative colitis has only been proven for cutaneous lesions but not for intestinal lesions of Kaposi's sarcoma.
  • We report for the first time, the expression of HHV8 (by using immunohistochemistry) in colonic Kaposi's sarcoma in a patient with an ulcerative colitis-related tumor.
  • At laparotomy, numerous Kaposi's sarcoma lesions were found in the small intestine, which were left in situ.
  • Forty months after surgery and following withdrawal of immunosuppressive therapy, the patient had no evidence of any disease and a normal abdominal and thoracic CT scan.
  • Cases of colorectal Kaposi's sarcoma complicating inflammatory bowel disease should be managed with a conservative approach and discontinuation of the immunosuppressive treatment.
  • However, discontinuation of the immunosuppression is not always possible and in those cases chemotherapy may be indicated.
  • [MeSH-major] Colitis, Ulcerative / drug therapy. Colorectal Neoplasms / complications. Herpesvirus 8, Human. Immunosuppressive Agents / therapeutic use. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / virology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273971.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


12. Atmatzidis KS, Pavlidis TE, Galanis IN, Papaziogas BT, Papaziogas TB: Malignant fibrous histiocytoma of the abdominal cavity: report of a case. Surg Today; 2003;33(10):794-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma originating from fibroblast cells, characterized by a high rate of metastasis or recurrence.
  • A computed tomography (CT) scan of the abdomen revealed multiple solid tumors in the peritoneal cavity.
  • We performed exploratory laparotomy and found at least 15 solid whitish tumors attached to the wall of the small intestine, as well as to the parietal peritoneum.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of the resected specimens established the definite diagnosis of a pleomorphic MFH.
  • The patient had an uneventful postoperative course and was given adjuvant chemotherapy.
  • We review the clinical picture of this tumor in the abdominal cavity, and discuss its diagnosis, pathogenesis, and treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Intestinal Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Intestine, Small. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14513333.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Talamonti MS, Goetz LH, Rao S, Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg; 2002 May;137(5):564-70; discussion 570-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.
  • HYPOTHESIS: This study was done to review the clinical presentation, surgical management, pathologic features, and prognostic factors for primary small-bowel cancers.
  • The distribution of tumors by histological features was as follows: adenocarcinoma (33%), carcinoid tumor (29%), lymphoma (19%), and sarcoma (19%).
  • Cumulative 5-year survival rate was 37% in the adenocarcinoma group, 64% in the carcinoid tumor group, 29% in the lymphoma group, and 22% in the sarcoma group.
  • Patient age, tumor location, histological grade, and use of chemotherapy and radiation therapy did not significantly influence survival.
  • The median time to recurrence was 16 months.
  • Twenty-one patients (16%) developed associated primary cancers.
  • [MeSH-major] Intestinal Neoplasms / mortality. Intestinal Neoplasms / surgery
  • [MeSH-minor] Actuarial Analysis. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoid Tumor / mortality. Carcinoid Tumor / surgery. Female. Humans. Intestine, Small. Lymphoma / mortality. Lymphoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Sarcoma / mortality. Sarcoma / surgery. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11982470.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They have predilection for the skin, lymph nodes, central nervous system, and small intestine.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


15. Khalid S, Adil SN, Vaziri IA: Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):88-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma in the absence of acute myeloid leukemia: a case report.
  • Granulocytic sarcoma is an extramedullary tumor composed of immature granulocytic precursor cells.
  • The most common sites of presentation are bone, periosteum, soft tissue, lymph node, skin, and infrequently small intestine.
  • It can occur without blood or bone marrow manifestations of leukemia and in this case, the diagnosis is difficult.
  • Subsequently, his biopsy slides were reviewed at our centre and were reported as granulocytic sarcoma.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bone Marrow / pathology. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Histocytochemistry. Humans. Leukemia, Myeloid, Acute / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasms. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474271.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


16. Delacruz V, Takahashi H, Nishida S, Tzakis A, Ruiz P: Segmental xanthomatosis of the small intestine. A case report and review of the literature. Hum Pathol; 2009 Jan;40(1):139-42
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental xanthomatosis of the small intestine. A case report and review of the literature.
  • Intestinal xanthomatosis is a rare, nonneoplastic lesion that may involve the small bowel in a localized or generalized way.
  • It may be a cause of clinically significant obstruction and should be included in the differential diagnosis with other causes of bowel obstruction, particularly in patients with history of radiation therapy or chemotherapy.
  • The patient was a 22-year-old man who developed intestinal obstruction 16 years after radiation therapy for Ewing sarcoma of the right hip.
  • [MeSH-major] Ileum / pathology. Intestinal Obstruction / etiology. Intestinal Obstruction / pathology. Intestine, Small / pathology. Xanthomatosis / complications
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Radiotherapy / adverse effects. Sarcoma, Ewing / radiotherapy. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jul;40(7):1052; author reply 1052 [19342078.001]
  • (PMID = 18755495.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


17. Palanivelu C, Rangarajan M, Senthilkumar R, Annapoorni S: Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: report of a case. Surg Today; 2009;39(7):606-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: report of a case.
  • Granulocytic sarcoma is an extramedullary tumor of immature myeloid cells which is often a forerunner to the development of acute myelogenous leukemia.
  • Granulocytic sarcoma of the gastrointestinal tract frequently involves the small intestine and often presents with abdominal pain and obstruction.
  • This type of manifestation has never before been reported.
  • The initial pathological findings were high-grade non-Hodgkin's lymphoma; immunohistochemistry confirmed a diagnosis of granulocytic sarcoma.
  • Chemotherapy is the treatment of choice and surgery is indicated only in the event of complications, such as bowel obstruction, bleeding, or perforation.
  • The prognosis of granulocytic sarcoma is similar to that of myeloid leukemia.
  • [MeSH-major] Intussusception / surgery. Jejunal Neoplasms / surgery. Sarcoma, Myeloid / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):865-6 [10690184.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 2):308-11 [9270534.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] J Nippon Med Sch. 2000 Oct;67(5):392-5 [11031375.001]
  • [Cites] Med Clin (Barc). 1995 Mar 18;104(10):377-80 [7707732.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12 ):2586-8 [9860434.001]
  • [Cites] Chirurg. 2002 Nov;73(11):1127-31 [12430065.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):555-9 [1985052.001]
  • [Cites] Hong Kong Med J. 2005 Jun;11(3):204-6 [15951586.001]
  • [Cites] J Fla Med Assoc. 1997 Feb;84(2):111-4 [9066237.001]
  • [Cites] World J Surg. 2000 Apr;24(4):421-9 [10706914.001]
  • [Cites] Am Surg. 2001 Aug;67(8):764-6 [11510579.001]
  • [Cites] Gastroenterol Hepatol. 2003 Jun-Jul;26(6):347-50 [12809571.001]
  • (PMID = 19562450.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol; 2005 Aug 20;23(24):5795-804
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
  • This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease.
  • The impact of initial dose on late resistance was mainly significant in patients with a high baseline granulocyte count (> 5.10(9)/L) and in patients with tumors of GI origin outside of the stomach and small intestine.
  • CONCLUSION: Our study identifies patients for whom initial and/or long-term treatment needs to be improved and patients who require a high initial dose.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Imatinib Mesylate. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110036.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-29; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


19. Sharykina NI, Bukhtiarova TA, Kudriavtseva IG, Pavlovskaia GP: [Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle]. Ukr Biokhim Zh (1999); 2004 Jan-Feb;76(1):123-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Study of influence of new antitumor preparations bifolar and chlofiden on rat liver protein biosynthesis in vivo and on sarcoma-45 in vitro was carried out using labeled precursor 3H-leucine.
  • It was shown that the preparations inhibited protein synthesis in normal and malignant tissues.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Ethylamines / pharmacology. Mitosis / drug effects. Neoplasm Proteins / biosynthesis. Phosphoramide Mustards / pharmacology. Protein Biosynthesis / drug effects. Sarcoma, Experimental / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Intestine, Small / drug effects. Intestine, Small / metabolism. Intestine, Small / pathology. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Neoplasm Transplantation. Rats. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909427.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chlofiden; 0 / Ethylamines; 0 / Neoplasm Proteins; 0 / Phosphoramide Mustards; 1950-04-5 / Preparation F-11
  •  go-up   go-down


20. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • The sarcoma component recurred in the remaining part of the left lung.
  • However, distant metastases occurred to the brain, liver, and small intestine, and digestive tract bleeding also occurred.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.
  • [MeSH-minor] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Chondrosarcoma / pathology. Humans. Intestinal Neoplasms / secondary. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y: Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos; 2000 Oct;28(10):1162-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
  • In this study, we investigated the tissue distribution and the metabolic fate of Oxo in rats after oral administration of S-1.
  • Oxo was mainly distributed to the intracellular sites of the small intestines in a much higher concentration than 5-FU, but little distributed to other tissues, including tumorous ones in which 5-FU was observed after oral administration of S-1.
  • Plasma concentration-time profiles of Oxo and its metabolites after i.v. and oral administration of S-1 revealed that Oxo was mainly converted to cyanuric acid in the GI tract.
  • Furthermore, the analysis of drug-related radioactivity in GI contents and in vitro studies suggested that Oxo was converted to cyanuric acid by two routes, the first being direct conversion by the gut flora in the cecum, and the second, conversion by xanthine oxidase or perhaps by aldehyde oxidase after degradation to 5-azauracil (5-AZU) by the gastric acid.
  • These results indicate that, although a part of the administered Oxo was degraded in the GI tract, Oxo was mainly distributed to the intracellular sites of the small intestines in a much higher concentration than 5-FU and that little was distributed to other tissues, including tumors.
  • [MeSH-minor] Administration, Oral. Allopurinol / pharmacology. Animals. Area Under Curve. Biotransformation. Carbon Radioisotopes. Chlorpromazine / pharmacology. Drug Combinations. Drugs, Chinese Herbal / pharmacology. Fluorouracil / blood. Fluorouracil / metabolism. Intestine, Small / metabolism. Male. Microsomes, Liver / drug effects. Microsomes, Liver / metabolism. Rats. Rats, Inbred Strains. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / metabolism. Tissue Distribution. Triazines / blood. Triazines / metabolism. Xanthine Oxidase / metabolism

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYANURIC ACID .
  • Hazardous Substances Data Bank. SODIUM CYANURATE .
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. Chlorpromazine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10997934.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carbon Radioisotopes; 0 / Drug Combinations; 0 / Drugs, Chinese Herbal; 0 / Pyridines; 0 / Triazines; 0 / shakuyaku-kanzoh-toh; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 63CZ7GJN5I / Allopurinol; 71-33-0 / 5-azauracil; EC 1.17.3.2 / Xanthine Oxidase; H497R4QKTZ / cyanuric acid; U3P01618RT / Fluorouracil; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


22. Liu JR, Wang SY, Lin YY, Lin CW: Antitumor activity of milk kefir and soy milk kefir in tumor-bearing mice. Nutr Cancer; 2002;44(2):183-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral administration of milk and soy milk kefirs to mice inoculated with sarcoma 180 tumor cells resulted in 64.8% and 70.9% inhibition of tumor growth, respectively, compared with controls.
  • In addition, oral administration of the two kefir types induced apoptotic tumor cell lysis.
  • Total immunoglobulin A levels for tissue extracts from the wall of the small intestine were also significantly higher for mice fed a milk kefir or a soy milk kefir regimen for 30 days.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cultured Milk Products / immunology. Gastrointestinal Neoplasms / drug therapy. Sarcoma, Experimental / drug therapy. Soybeans / immunology
  • [MeSH-minor] Animals. Body Weight / drug effects. Body Weight / immunology. Disease Models, Animal. Drug Screening Assays, Antitumor / statistics & numerical data. Female. Immunoglobulin A / drug effects. Immunoglobulin A / immunology. Mice. Mice, Inbred ICR. Mucous Membrane / immunology. Peyer's Patches / drug effects. Peyer's Patches / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12734066.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin A
  •  go-up   go-down


23. Amtmann E, Zöller M, Wesch H, Schilling G: Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother Pharmacol; 2001 Jun;47(6):461-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Platinum complexes are essential tools for cancer treatment despite their toxic side effects.
  • To demonstrate low in vivo toxicity the effects of thioplatin on body weight, blood urea nitrogen, white blood cell count and the histopathological appearance of small intestines and kidneys were evaluated at doses that displayed antitumoral effects against human small-cell lung cancer and human colorectal cancer xenotransplants in nude mice.
  • Thioplatin displayed antitumoral activity without severe side effects such as weight loss, renal ischaemia, destruction of villi in the small intestine or leukopenia as observed at comparable doses of cisplatin.
  • In vivo studies with human tumour xenografts in nude mice showed a therapeutic index of thioplatin five to ten times higher than that of cisplatin.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cross-Linking Reagents / therapeutic use. Organoplatinum Compounds / therapeutic use. Sulfur Compounds / therapeutic use
  • [MeSH-minor] Animals. Bone Marrow / drug effects. Carcinoma, Small Cell / drug therapy. Cisplatin / adverse effects. Cisplatin / therapeutic use. Colorectal Neoplasms / drug therapy. DNA, Neoplasm / drug effects. DNA, Neoplasm / metabolism. Drug Screening Assays, Antitumor. HeLa Cells. Humans. Hydrogen-Ion Concentration. Leukemia L1210 / drug therapy. Lung Neoplasms / drug therapy. Mice. Mice, Nude. Sarcoma 180 / drug therapy. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11459197.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cross-Linking Reagents; 0 / DNA, Neoplasm; 0 / Organoplatinum Compounds; 0 / Sulfur Compounds; 0 / thioplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Lee KH, Fiedler P, Passarelli J, Bobrow S: Autoimmune hemolytic anemia associated with postirradiation malignant stromal tumor (leiomyosarcoma) of the jejunum. Ann Diagn Pathol; 2000 Dec;4(6):367-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient who presented with autoimmune hemolytic anemia and small bowel obstruction secondary to a malignant stromal tumor (leiomyosarcoma) of the jejunum, 25 years postchemotherapy and radiation treatment for stage IIA Hodgkin's disease.
  • The patient was treated with corticosteroid therapy and surgical resection of the jejunal tumor.
  • We conclude that autoimmune hemolytic anemia may be an unusual presentation for postirradiation sarcoma.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Intestinal Obstruction / etiology. Intestine, Small / pathology. Jejunal Neoplasms / etiology. Leiomyosarcoma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Radiotherapy / adverse effects


25. Maity P, Chakraborty S, Bhattacharya P: A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase. J Exp Clin Cancer Res; 2000 Jun;19(2):161-4
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase.
  • Distribution of glutamine level in different tissues of tumor bearing mice such as brain, liver, kidney, spleen, large and small intestine and the tumor itself were studied in three solid tumor models, viz, Ehrlich ascites carcinoma, Sarcoma-180 and methylcholanthrene induced carcinoma.
  • Tumor bearing mice were subjected to therapy for 7 days with the glutaminase purified from malignant S-180 cell.
  • The results exhibit a significant decrease in tumor burden after enzyme therapy.
  • Host tissue glutamine levels were significantly elevated in tumor bearing untreated mice in comparison to the normal ones, while significant lower values were obtained after enzyme therapy.
  • It therefore appears that elevated levels of glutamine in host tissue are associated with the tumor burden.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Glutaminase / therapeutic use. Glutamine / metabolism. Sarcoma 180 / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Brain / metabolism. Intestines / metabolism. Kidney / metabolism. Liver / metabolism. Male. Methylcholanthrene / toxicity. Mice. Spleen / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965812.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 56-49-5 / Methylcholanthrene; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


26. Kumar B, Bommana V, Irani F, Kasmani R, Mian A, Mahajan K: An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma. QJM; 2009 Jul;102(7):491-3
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
  • [MeSH-major] Intestinal Obstruction / etiology. Intestine, Small. Sarcoma, Myeloid / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433489.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement